SCHEMBL64201

SCHEMBL64201

C1CC(N2CCNCC2)C1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.60
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HRH3 Q9Y5N1 4/20 0.40
CYP2D6 P10635 1/20 0.37
L3MBTL3 Q96JM7 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CHRNB2 P17787 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
PHGDH O43175 1/20 0.34
MGLL Q99685 1/20 0.34
OPRM1 P35372 2/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OGFRL1 Q5TC84 1/20 0.34
SLC18A3 Q16572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL452523 0.97 HTR6 (0.58) HTR6HPGDKMT2ASMN1; SMN2HRH3
Hydrochloric Acid SCHEMBL450071 0.97 HTR6 (0.58) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL271868 0.94 HTR6 (0.67) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL524430 0.93 HTR6 (0.59) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL1267270 0.92 HTR6 (0.64) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL943337 0.92 HTR6 (0.64) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL451992 0.92 HTR6 (0.64) HTR6HPGDKMT2ASMN1; SMN2HRH3
SCHEMBL43171 0.92 HTR6 (0.64) HTR6HPGDKMT2ASMN1; SMN2HRH3
Hydrochloric Acid SCHEMBL452359 0.92 HTR6 (0.64) HTR6HPGDKMT2ASMN1; SMN2HRH3
Hydrochloric Acid SCHEMBL4321509 0.91 HTR6 (0.57) HTR6HPGDKMT2ASMN1; SMN2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023166351-A1 HISTAMINE H3 RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF 杭州百诚医药科技股份有限公司 2023-09-07 WO claimed
CN-113200908-A Tertiary amine-containing anthranilamide compound and preparation and application thereof 南华大学 2021-08-03 CN claimed
CN-104470911-B Urethane/urea derivative 诺华股份有限公司 2018-04-06 CN claimed
EP-2440204-B1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-12-18 EP claimed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US claimed
CN-102458402-B Nicotinamide compounds useful as kinase modulators BRISTOL MYERS SQUIBB CO 2013-10-02 CN claimed
CN-102458402-A Nicotinamide compounds useful as kinase modulators BRISTOL MYERS SQUIBB CO 2012-05-16 CN claimed
EP-2440204-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS Bristol-Myers Squibb Company (US) 2012-04-18 EP claimed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US claimed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO claimed
WO-2010133544-A1 PIPERAZINE AND AMINOPYRROLIDINE COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2010-11-25 WO claimed
US-20260048068-A1 PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES HANGZHOU BIO SINCERITY PHARMA TECH CO LTD (CN) 2026-02-19 US disclosed
EP-4581017-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2025-07-09 EP disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
CN-120152975-A Pyrazolo [1,5-a ] pyridine and imidazo [1,2-a ] pyridine derivatives as FGFR3 inhibitors for the treatment of cancer 伊莱利利公司 2025-06-13 CN disclosed
WO-1990006921-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1990-06-28 WO disclosed
EP-0322643-A1 Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use BAYER AG (DE) 1989-07-05 EP disclosed
EP-0313974-A1 N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals BAYER AG (DE) 1989-05-03 EP disclosed
US-4806539-A 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acids and antibacterial agents containing them BAYER AKTIENGESELLSCHAFT (DE) 1989-02-21 US disclosed
EP-0224178-A1 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)-3-quinoline-carboxylic acids, process for their preparation and antibacterial compositions containing them BAYER AG (DE) 1987-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048068-A1 PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES HRH3, HRH2, HRH4 HTR6 6/4885HPGD 2546/4885KMT2A 1071/4885
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT HTR6 3184/4885HPGD 225/4885KMT2A 2299/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A HTR6 2385/4885HPGD 3777/4885KMT2A 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.